Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

• Simon T. Durrant,
• Arnon Nagler,
• Paola Guglielmelli,
• David Lavie,
• Philipp le Coutre,
• Heinz Gisslinger,
• Charles Chuah,
• Margherita Maffioli,
• Savita Bharathy,
• Tuochuan Dong,
• Monika Wroclawska,
• Joaquin Martinez Lopez

Affiliations

Simon T. Durrant

Royal Brisbane Hospital, Herston, Australia

Arnon Nagler

ALWP Office, Hospital Saint Antoine, Paris, France

Paola Guglielmelli

CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

David Lavie

Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Philipp le Coutre

Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany

Heinz Gisslinger

Medical University of Vienna, Vienna, Austria

Charles Chuah

Singapore General Hospital, Duke-NUS Medical School, Singapore

Margherita Maffioli

Hematology Department, ASST Sette Laghi - Ospedale di Circolo, Varese, Italy

Savita Bharathy

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Tuochuan Dong

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Monika Wroclawska

Novartis Pharma AG, Basel, Switzerland

Joaquin Martinez Lopez

Hematology Department, Hospital 12 de Octubre, CNIO, Univ Complutense, CIBERONC, Madrid, Spain